Introduction
============

Every day millions of cells die in the human body, producing cellular corpses and material that must be disposed of. Dead cells originating from the body's surfaces can simply be sloughed off with little or no consequence. In contrast, cells that die within tissues must be removed, a task typically undertaken by phagocytic cells of the immune system. This system has dual purpose. If the cell death is necrotic, due to viral or bacterial infection, the clearance of diseased cells assists in removing the insult and activating specific immunity against the offending cell-associated Ag. If the cell death is a part of natural tissue homeostasis, i.e., apoptotic cell death, the clearance of dead cells can function to maintain peripheral tolerance and prevent autoimmune disease. Within this context apoptotic cell death is historically considered an immunologically silent event.

Though seemingly simple in concept, continuing research on apoptosis and the clearance of apoptotic cells has revealed the complexity of this system. As a result, a multitude of factors have been identified that influence whether tolerance or immunity is established against cell-associated Ag upon uptake of apoptotic cells. These factors include, but are not limited to, the type of cell that is dying, how death was induced, in which tissue the death occurred, the recognition and uptake by phagocytic cells, the type of phagocyte involved in the uptake, and the resulting micro-environment (Poon et al., [@B108]). For example, cells treated with irradiation or chemotherapy become apoptotic but tend to be immunogenic (Ronchetti et al., [@B119]; Janssen et al., [@B74]; Green et al., [@B54]; Reboulet et al., [@B112]; Ferguson et al., [@B46]). In this context immunity probably results from the irradiation or chemical induced release of damage associated molecular proteins (DAMPS) such as high mobility group box 1 (HMGB1), uric acid/mono-sodium urate crystals, heat shock proteins, and nucleotide structures from the dying cell (Green et al., [@B54]; Poon et al., [@B108]). These signals, similar to those released during necrotic cell death, provoke immunity instead of tolerance. Though important, signals released by the dying cell do not fully explain immunologic outcome. Studies wherein identically treated cells induce tolerance if injected intravenously, yet immunity if injected subcutaneously illustrated how the location of cell death and, more importantly, the type of antigen presenting cell (APC) performing the uptake crucially affect immunity or tolerance. Subsequent studies correlated this induction of immunity or tolerance specifically with the dendritic cell (DC) subset that took up and processed the injected cells (Belz et al., [@B12]; Ferguson et al., [@B47]; Iyoda et al., [@B73]; Green et al., [@B54]).

Dendritic Cells and the Presentation of Cell-Associated Antigens
================================================================

In the evolution of the vertebrate immune system, DCs have filled the role of premier APC. All APCs characteristically take up, process and present exogenous antigens to CD4^+^ T cells within the context of MHC class II molecules. Uniquely, DCs are additionally able to shuttle a portion of "eaten" antigens into the MHC class I restricted pathway, a pathway that in all other cell types is reserved for presentation of endogenous proteins. In DCs, this cross-presentation process allows exogenous Ag, including cell-associated Ag originating from dead and dying cells, to be effectively presented to CD8^+^ T cells. Seminal work over the last decade addressing uptake and processing of cell-associated Ag by phagocytes has elucidated common mechanisms utilized by cross-presenting DC subsets that influence cross-presentation and the resulting immune response. Successful cross-presentation is characterized by specific uptake, distinct endosomal/lysosomal trafficking, delayed lysosomal acidification, and Ag persistence compared to non-cross-priming DC populations. Also, the cytokine profile by which each DC subset responds to uptake of dying cells influences these processes and the final potency of the Ag-specific response.

Mouse splenic DC subsets during steady state
--------------------------------------------

As a result of ongoing research, the system by which DCs are classified continues to change. Currently, as new subsets are discovered, characterization often places them into one of two groups: steady state conventional DCs (cDCs) or non-conventional DCs (Kushwah and Hu, [@B88]). This initial classification is based on lineage, function, and location, with each subset being identified by the presence or absence of different cell surface markers. Steady state cDCs, as the name suggests, are present and function continually, even during inflammation, and include subsets found in the lymphoid organs as well as migratory subsets present in the tissues. Non-conventional DCs are mostly comprised of monocyte-derived DCs subsets, populations which are highly enriched during inflammation and thus are often referred to as inflammatory DCs (Shortman and Liu, [@B139]; Heath et al., [@B62]; Shortman and Naik, [@B140]; Liu et al., [@B95]; Kushwah and Hu, [@B88]). DCs found in non-lymphoid tissue regardless of whether formally categorized as steady state conventional or monocyte-derived non-conventional, are typically classified by the tissue in which they are found and the presence or absence of CD103, CD11b, langerin (for skin associated subsets), or the chemokine receptor CX3CR1 (Kushwah and Hu, [@B88]). Though some of these subsets are capable of cross-presentation, this review focuses on those subsets present in the spleen. We refer those interested to several publications that more completely dissect the lineages, functionality and surface expression of various markers in these other DC populations (Shortman and Liu, [@B139]; Heath et al., [@B62]; Shortman and Naik, [@B140]; Liu et al., [@B95]; del Rio et al., [@B31]; Liu and Nussenzweig, [@B94]; Shortman and Heath, [@B138]; Kushwah and Hu, [@B88]). Plasmacytoid DCs (pDCs), a subset also present in the spleen during steady state, are functionally distinct from both cDCs and non-conventional subsets, but possess a common precursor with cDCs subsets. In spite of this connected lineage, functional differences between cDCs and pDCs complicates the exact placement of the latter subset and, thus, has led to controversy. As a result, some researchers place pDCs with non-conventional DCs while others place them within a distinct group called pre-DCs or within their own category (Shortman and Liu, [@B139]; Shortman and Naik, [@B140]; Liu and Nussenzweig, [@B94]; Kushwah and Hu, [@B88]).

Conventional DCs and pDCs present in spleen and lymph nodes are distinguished by differential expression of CD11c, B220, and PDCA-1. Splenic cDCs lack B220 and PDCA-1 (Figure [1](#F1){ref-type="fig"}A) and can be further divided into four subpopulations characterized by the presence or lack of various markers (Table [1](#T1){ref-type="table"}): (1) CD8α DCs (CD8α^+^, CD4^−^, CD11b^−^); (2) CD11b DCs (CD8^−^, CD4^−^, CD11b^+^); (3) CD4 DCs (CD8^−^, CD4^+^, CD11b^+^); or (4) merocytic DCs (mcDCs)/CD8^−^, CD4^−^, CD11b^−^ DC (Figure [1](#F1){ref-type="fig"}A; Janssen et al., [@B74]; Reboulet et al., [@B112]; Shortman and Heath, [@B138]; Hennies et al., [@B64]; Kushwah and Hu, [@B88]). We have investigated, and thus will discuss in this review, the uptake of cell-associated Ag under steady state conditions and their cross-presentation within four splenic DC subgroups -- CD8α DCs, CD11b DCs (which includes the CD4^+^ subset), mcDC/CD8^−^, CD4^−^, CD11b^−^ DC, and pDCs.

![**Differential uptake of dying cells and subsequent cross-priming by splenic DC populations**. **(A)** Live or irradiated CFSE-labeled OVA-expressing splenocytes were injected (i.v.) into mice. After 2 h uptake CFSE-labeled material was analyzed in indicated splenic DC subsets. **(B)** Mice were i.v. injected with irradiated OVA-expressing K^b^-deficient splenocytes (Ehst et al., [@B40]). Cross-presentation of H-2K^b^ restricted OVA~257--264~ was assessed by activation of an OVA~257--264~-specific T cell hybridoma, B3Z (Karttunen et al., [@B79]). **(C)** Characteristic cross-priming -- as determined by CFSE dilution -- of OVA~257--264~-specific CD8^+^ T cells by purified DCs upon *in vitro* culture with apoptotic OVA-expressing K^b^-deficient cells.](fimmu-03-00041-g001){#F1}

###### 

**Characteristics of splenic DC subsets**.

                                                          CD8^+^ DC   CD11b^+^ DC   CD8^−^ CD4^−^ mcDC   pDC   Reference
  ------------------------------------------------------- ----------- ------------- -------------------- ----- -------------------------------------------------------------------------------
  *Itgax*/CD11c                                           +++         +++           +++                  ++    Hashimoto et al. ([@B60])
  *itgam*/CD11b                                           −           +++           \+                   −     Vremec et al. ([@B154]), Vremec and Shortman ([@B155])
  *Sirpa*/CD172a                                          −/+         +++           −/+                  +/−   Lahoud et al. ([@B90])
  *CD4*                                                   −           ++            −                    −     Crowley et al. ([@B28]), Vremec et al. ([@B154])
  *CD8a*                                                  +++         −             −                    −     Shortman and Heath ([@B138])
  *itgae*/CD103                                           ++          −             −                    −     Bedoui et al. ([@B11]), McLellan et al. ([@B99]), Qiu et al. ([@B111])
  *CD205*                                                 ++          −             −/+                  −     Kraal et al. ([@B84]), Shrimpton et al. ([@B141])
  *XCR1*                                                  ++          −             \+                   −     Crozat et al. ([@B29]), Robbins et al. ([@B116])
  *IRF8*                                                  ++          −             ++                   ++    Aliberti et al. ([@B3]), Schiavoni et al. ([@B130]), Tailor et al. ([@B145])
  *IRF4*                                                  −/+         ++            −/+                  −/+   Hashimoto et al. ([@B60])
  *MHC II*                                                +++         +++           +++                  ++    Wilson et al. ([@B157])
  *CD80*                                                  \+          \+            \+                   −     Shortman and Heath ([@B138]), Wilson et al. ([@B157])
  *CD86*                                                  ++          \+            ++                   +/−   Shortman and Heath ([@B138])
  *CD40*                                                  \+          ++            \+                   \+    Shortman and Heath ([@B138])
  *TLR3*                                                  +++         \+            +++                  −     Edwards et al. ([@B39])
  *TLR7*                                                  −           \+            −                    ++    Edwards et al. ([@B39])
  *TLR9*                                                  \+          \+            \+                   ++    Edwards et al. ([@B39])
  Clec9a                                                  +++         \+            +++                  \+    Sancho et al. ([@B123])
  CLec12a                                                 +++         \+            nd                   nd    Lahoud et al. ([@B89])
  Havcr1/tim1                                             −           −             −                    +++   Kobayashi et al. ([@B82])
  Havcr2/tim3                                             +++         +++           +++                  −     Nakayama et al. ([@B102])
  Tim 4                                                   \+          +/−           \+                   \+    Albacker et al. ([@B1]), Kobayashi et al. ([@B82])
  Treml2                                                  \+          \+            ++                   +++   Hemmi et al. ([@B63])
  Treml4                                                  +++         ++            ++                   −     Hemmi et al. ([@B63])
  CD36                                                    +++         ++            +++                  +/−   Albert et al. ([@B2])
  MR                                                      −           \+            −                    −     Burgdorf et al. ([@B19]), Burgdorf et al. ([@B20]), Sallusto et al. ([@B121])
  Lox1                                                    \+          −             \+                   −     Delneste et al. ([@B33]), Erwig and Henson ([@B44]), Oka et al. ([@B104])
  FcγR2b                                                  \+          ++            \+                   \+    Amigorena ([@B5]), Rodriguez et al. ([@B118])
  Cystatin C                                              ++          \+            ++                   \+    El-Sukkari et al. ([@B41])
  NOX2 gpphox91                                           +/−         ++            \+                   nd    Savina et al. ([@B127])
  **CYTOKINE INDUCTION UPON UPTAKE OF APOPTOTIC CELLS**                                                        
  IL-12                                                   −           −             −                    −     Morelli et al. ([@B100])
  IL-10                                                   −           ++            −                    −     Hennies et al. ([@B64])
  TGFβ                                                    +/−         ++            −                    −     Hennies et al. ([@B64]), Yamazaki et al. ([@B161])
  Type I IFN                                              −           −             ++                   −     Janssen et al. ([@B74]), Lorenzi et al. ([@B96])

*Data compiled from indicated literature and unpublished DNA arrays*.

*nd, not done*.

CD8α DCs
--------

The CD8α DC, classically considered to be the major cross-presenting DC subset in the mouse spleen, is located in the T cell zone of the spleen and has repeatedly been shown to effectively cross-present beads, soluble Ag, and cell-associated Ag (Figures [1](#F1){ref-type="fig"}B,C; den Haan et al., [@B35]; Pooley et al., [@B107]; Heath et al., [@B62]; Belz et al., [@B13]; Schnorrer et al., [@B131]). The development of CD8α DCs is dependent on Flt3L-STAT3 signaling. While cDC development in general requires the transcription factors Ikaros, and PU.1 (Wu et al., [@B160]; Anderson et al., [@B7]; Guerriero et al., [@B57]; Allman et al., [@B4]; Wu and Liu, [@B159]), the CD8α DC lineage commitment is also dependent on Batf3, IRF-8, and Id2 (Schiavoni et al., [@B130]; Hacker et al., [@B58]; Hildner et al., [@B66]). This DC subset, in addition to being CD8α^+^, also expresses DEC205, XCR1, and Clec9a (Vremec et al., [@B154]; Sancho et al., [@B122]; Shortman and Heath, [@B138]; Crozat et al., [@B29]). Depending on age and strain of mouse, up to 70% of CD8α DCs co-express CD103, which has been suggested to represent a developmental stage or activation state within the CD8α DC population or a CD8^+^ subset with distinct functionality (Pribila et al., [@B109]; Qiu et al., [@B111]; del Rio et al., [@B31]; Shortman and Heath, [@B138]). CD8α DCs take up dead cells more readily than other splenic DC subsets (Figure [1](#F1){ref-type="fig"}A; Iyoda et al., [@B73]; Schulz and Reis e Sousa, [@B134]; Schnorrer et al., [@B131]) and have been implicated in the induction and maintenance of CD8^+^ T cell tolerance to cell-associated Ag in models of autoimmunity and transplantation (Kurts et al., [@B86], [@B87]; Hawiger et al., [@B61]; Belz et al., [@B12]; Bonifaz et al., [@B15]; Scheinecker et al., [@B129]; Shortman and Heath, [@B138]). This subset's importance in the cross-presentation of cell-associated Ag is further supported by a dramatic reduction of anti-tumor immunity in mice deficient in Batf3, a gene crucial for the development of the CD8α DC precursor (Hildner et al., [@B66]).

CD11b DCs
---------

Splenic CD11b DCs reside in the marginal zone of the spleen and predominantly co-express CD4, DCIR2, and Sirp-α (Crowley et al., [@B28]; Pulendran et al., [@B110]; Maldonado-Lopez and Moser, [@B98]; Lahoud et al., [@B90]). CD11b DC development is governed by transcription factors IRF2/4 (Honda et al., [@B70]; Ichikawa et al., [@B71]; Suzuki et al., [@B144]) and RelB (Burkly et al., [@B21]; Weih et al., [@B156]; Wu et al., [@B158]).

While CD11b DCs display great potential for phagocytosis of proteins, beads/particles, and bacteria, their capacity for cross-presentation under steady state conditions is poor. Moreover, CD11b DCs display weak phagocytosis of apoptotic cells and no role has been described for these cells in cross-presentation to cell-associated Ag under steady state conditions (Figures [1](#F1){ref-type="fig"}A--C; den Haan et al., [@B35]; Pooley et al., [@B107]; Iyoda et al., [@B73]; Schulz and Reis e Sousa, [@B134]; Morelli et al., [@B100]; Schnorrer et al., [@B131]).

Plasmacytoid dendritic cells
----------------------------

Splenic pDCs are defined by strong expression of both B220 and PDCA-1 and are predominantly located in the T cell area and red pulp. While there is some discussion on the exact delineation of pDC with regard to shared precursors with other cDC, research has shown the requirement for the transcription factors E2-2, IRF8, and Spi-B (Schiavoni et al., [@B130]; Schotte et al., [@B132]; Cisse et al., [@B27]). Although pDCs are poor at taking up cell-associated Ag, depletion studies have shown that pDCs are critical in the induction of tolerance after intravenous injection of apoptotic cells. Such tolerance, however, does not require direct pDC--apoptotic cell interactions, but rather soluble mediators from marginal zone macrophages (Bonnefoy et al., [@B16]).

Merocytic DCs/CD8^−^, CD4^−^, CD11b^−^ DC
-----------------------------------------

Over the recent years various laboratories have identified splenic DCs that lack the conventional markers (CD8α^−^, CD11b^−^, CD4^−^; Figures [1](#F1){ref-type="fig"}A--C; Hochrein et al., [@B68]; Naik et al., [@B101]; Janssen et al., [@B74]; Vremec et al., [@B153]; Bedoui et al., [@B10]; Katz et al., [@B80]; Reboulet et al., [@B112]; Hennies et al., [@B64]). Generally, these populations are relatively small and only comprise \<1--10% of the DC in a naïve steady state spleen. Several of these DC populations have been shown to cross-present antigens in protein (Vremec et al., [@B153]) or cell-associated form (Bedoui et al., [@B10]; Reboulet et al., [@B112]; Hennies et al., [@B64]). Flt3L treatment of mice significantly increases the frequency of these DCs, and cells with similar features can be generated by *in vitro* Flt3L bone-marrow cultures (Bedoui et al., [@B10]; Reboulet et al., [@B112]; Hennies et al., [@B64]).

During the course of our work we have named the CD8α^−^ CD11b^−^ CD4^−^ DC in the naïve spleen mcDCs due to the smaller particles (meros = particle) characteristically taken up by these cells (Figure [2](#F2){ref-type="fig"}C) and will use this name throughout this review (Reboulet et al., [@B112]). Like CD8α DCs, mcDCs express XCR1, Clec9a, and are Sirp-α negative, but in contrast are DEC205^−^, CD103^−^, and CD11b^−/dull^ (Table [1](#T1){ref-type="table"}). It has been suggested that this marker negative subset is a precursor to the CD8α DCs (Janssen et al., [@B74]; Bedoui et al., [@B10]), a hypothesis supported by the presence of Clec9a and CD24, surface molecules shown to be present on the immediate precursors of CD8α DCs that lack CD8 and DEC205 expression (Sathe and Shortman, [@B124]; Shortman and Heath, [@B138]; Kushwah and Hu, [@B88]). CD8α^−^ CD11b^−^ CD4^−^ DC obtained from Flt3L treated mice readily convert into CD8α DCs upon transfer (Bedoui et al., [@B10]). However, only a small fraction of CD8α^−^ CD11b^−^ CD4^−^ DC/mcDC from naïve spleens convert to CD8α DCs (Reboulet et al., [@B112]) suggesting that mcDCs are either "long-term" CD8α DC precursors that are relatively resistant to conversion or a stable population that possesses unique functionality and marker expression compared to other known precursors.

![**Splenic DC subsets differentially take up cellular particles influencing particle frequency and size**. **(A)** Transmission electron microscopy (TEM) images characterizing uptake of irradiated splenocytes by purified DC subsets after 4 h co-culture: N, nucleus; arrows, apoptotic material. **(B,C)** ImageStream analysis of the frequency and size of internalized CFSE-labeled particles after 20 h co-culture with CFSE-labeled irradiated cells.](fimmu-03-00041-g002){#F2}

Merocytic DCs take up cellular material from dead and dying cells, though be it less than CD8α DCs (Figure [1](#F1){ref-type="fig"}A). Though mcDCs take up less apoptotic cell material they show extended cross-priming of CD8^+^ T cells due to prolonged storage of cell-associated Ag (Reboulet et al., [@B112]). Importantly, mcDCs prime both CD4^+^ and CD8^+^ T cells to cell-associated Ag (Figures [1](#F1){ref-type="fig"}B,C; Janssen et al., [@B74]; Reboulet et al., [@B112]). CD4^+^ T cell activation is important in the induction of immunity against cell-associated Ag as CD8^+^ T cells become tolerant without sufficient CD4^+^ T cell help (Janssen et al., [@B76], [@B75]; Griffith et al., [@B55]). CD8^+^ T cells primed by mcDC to cell-associated Ag show greater capacity for primary expansion, cytokine production, and memory formation on a per cell basis than those primed by CD8α DC (Janssen et al., [@B74]; Katz et al., [@B80]; Reboulet et al., [@B112]; Hennies et al., [@B64]).

Merocytic DC have been associated with the breaking of tolerance and acceleration of immune responses to cell-associated Ags. Treatment of tumor bearing mice with mcDC previously exposed to irradiated tumor cells, resulted in tumor suppression and increased host survival through the activation of naïve tumor-specific CD8^+^T cells as well as the reinvigoration of tumor-specific T cells that had been rendered non-responsive by the tumor *in vivo* (Reboulet et al., [@B112]). Dysregulation of the mcDC compartment has also been associated with the development of autoimmunity; mcDCs are more numerous and more biologically active in the non-obese diabetic (NOD) mouse model of type I diabetes and absolute numbers correlate with disease development and progression. Transfer of mcDCs -- loaded with irradiated islet cells-- transferred diabetes in young NOD recipients. Moreover, when purified from the pancreatic lymph nodes of overtly diabetic NOD mice, mcDCs break peripheral tolerance to beta antigens *in vivo* and induce the rapid onset of T cell-mediated type I diabetes in young NOD mice (Katz et al., [@B80]).

Recognition and Differential Uptake of Dead and Dying Cells
===========================================================

Though little is known regarding the influence of clathrin-mediated uptake vs. phagocytosis or macropinocytosis on cross-presentation pathways of cell-associated Ag, uptake and cross-presentation of cellular material is largely thought to be receptor mediated (Erwig and Henson, [@B44]).

Recognition through phagocytic receptors
----------------------------------------

As a cell becomes apoptotic, the steady state "don't eat me" signals of viable cells are lost and replaced through a series of morphological and biochemical changes (Elward and Gasque, [@B42]; Erwig and Henson, [@B44]; Poon et al., [@B108]). The most prominent and perhaps best-characterized change is the exposure of phosphatidylserine (PS) on the surface of the dying cell. Once PS is exposed, it can be recognized by a number of bridging molecules including milk fat globular-EGF factor 8 protein (MFG-E8; Borisenko et al., [@B17]; Hanayama et al., [@B59]), growth arrest-specific 6 (Gas6; Ishimoto et al., [@B72]; Scott et al., [@B135]), β2-glycoprotein I (β2-GPI; Balasubramanian et al., [@B9]), and serum Protein S (Erwig and Henson, [@B44]; Krysko and Vandenabeele, [@B85]; Poon et al., [@B108]). Many of these bridging molecules then facilitate recognition by receptors on the surface of the phagocyte, including the integrins αvβ3 or αvβ5 (Borisenko et al., [@B17]; Hanayama et al., [@B59]; Erwig and Henson, [@B44]). Additionally, the apoptotic cell and other bridging molecules like TSP-1 are recognized by phagocytic receptors such as Tim-1, Tim-3, and Tim-4 (Kobayashi et al., [@B82]; Nakayama et al., [@B102]; Albacker et al., [@B1]), CD36 (Albert et al., [@B2]), Treml2 and Treml4 (Hemmi et al., [@B63]), DEC205 (Shrimpton et al., [@B141]), class A scavenger receptors (Platt et al., [@B106]), Lox-1 (Oka et al., [@B104]), and various C-type lectins including Clec9a (DNGR1; Krysko and Vandenabeele, [@B85]; Sancho et al., [@B122]; Poon et al., [@B108]; Shortman and Heath, [@B138]). While the seemingly overabundance of receptors involved in dying cell uptake stresses the importance of apoptotic cell removal in the maintenance of immune homeostasis, it is becoming apparent that these molecules are not merely redundant, but may distinctly influence APC behavior, and, thus, guide specific responses toward cell-associated antigens under various settings (Bratton and Henson, [@B18]; Erwig and Henson, [@B44]; Krysko and Vandenabeele, [@B85]).

Cross-presentation, but not necessarily cross-priming, of cell-associated Ag is generally enhanced when uptake is mediated by DEC205 (Bonifaz et al., [@B15]), Clec9a (Sancho et al., [@B123], [@B122]), Lox-1(Delneste et al., [@B33]), or Fc gamma R (Regnault et al., [@B113]; Rodriguez et al., [@B118]; Amigorena, [@B5]; den Haan and Bevan, [@B34]; Kalergis and Ravetch, [@B77]; Flinsenberg et al., [@B50]). Uptake via the mannose receptor has also been implicated in cross-presentation pathways, but its relevance has thus far only been shown within the context of soluble Ag, not cell-associated Ag (Burgdorf et al., [@B19], [@B20]). Comparison of the transcriptome of the four DC subsets suggests the most similarity between mcDCs and CD8α DCs with regard to the expression of molecules involved in the recognition and uptake of dying cells. However, some receptors are still restricted to one subset -- as is the case for DEC205 and CD8α DCs -- or have differential expression/different levels of expression, resulting in unique patterns for each subset (Table [1](#T1){ref-type="table"}).

Consistent with receptor-mediated uptake leading to cross-presentation, both CD8α DCs and mcDCs appear to take up cellular material via a classical receptor-mediated phagocytic process. Transmission electron microscopy (TEM)of CD8α DCs and mcDCs exposed to dying cells predominantly shows the presence of small particles of phagocytosed material tightly surrounded by a double membrane (Figure [2](#F2){ref-type="fig"}A). In contrast, CD11b DCs appear to use a more macropinocytic mechanism resulting in the uptake of larger particles and inclusion of extracellular solutes and fluids (Figures [2](#F2){ref-type="fig"}A,C).

Particle size and frequency
---------------------------

Our studies and the work of others indicate that the method of uptake, i.e., receptor-mediated phagocytosis vs. macropinocytosis, influences the particle size taken up by APCs (Rejman et al., [@B115]). While particle size determines the total amount of Ag available to the cell, a growing body of literature indicates that particle size also affects intracellular trafficking, the kinetics of phagosomal pH, and thereby cross-presentation (Fifis et al., [@B48]; Rejman et al., [@B115]; Tran and Shen, [@B147]). Cross-presentation has been shown to be enhanced when Ag are bound onto particles between the range of 0.5 and 3 μ (Tran and Shen, [@B147]). However, it is likely that the optimal size for cross-presentation will be affected by the composition of the particle, the receptors involved in the uptake and the nature of the cell.

Transmission electron microscopy combined with ImageStream technology, a flow cytometric based method that allows for quantitative image analysis on vast number of cells, confirmed that cross-presenting splenic DCs differentially take up material from dead and dying cells as measured by total particles per cell and the overall particle size. CD8α DCs and mcDCs not only take up particles of dying cells more readily, but also preferentially take up smaller particles than CD11b DCs (Figures [2](#F2){ref-type="fig"}B,C), a size differential that most likely facilitates the entrance of cell-associated Ag into cross-presentation pathways (Fifis et al., [@B48]; Rejman et al., [@B115]; Tran and Shen, [@B147]).

Interestingly, upon exposure to dead and dying cells, mcDCs generally take up a comparable number of particles/cell to CD8α DCs, but these particles are typically smaller in size (Figures [2](#F2){ref-type="fig"}B,C; Reboulet et al., [@B112]). While the mcDCs takes up a lower "net amount" of Ag, the smaller particle size might expedite the export to the cytosol which would facilitate Ag processing (Rodriguez et al., [@B118]; Rock et al., [@B117]).

Antigen Trafficking, Processing, and Loading
============================================

Antigen trafficking and vesicle acidification
---------------------------------------------

Upon uptake, cellular material from dying cells is found within early phagosomes -- or sorting endosomes -- characterized by the presence of the early endosomal markers EEA-1, Rab5, PI(3)*P*, syntaxin 13, transferrin, and vesicle-associated membrane protein 3(VAMP-3; Vieira et al., [@B151]; Peng and Elkon, [@B105]). The phagosome is transformed into a phagolysosome through a progressive maturation process that is dependent on the sequential fusion of endosomes and lysosomes with the internalized phagosome. Most recently this maturation process and antigen cross-presentation was shown to be regulated by the SNARE protein Sec22b through its control of ER-resident protein recruitment to phagosomes (Cebrian et al., [@B22]). Late endosomes/late phagosomes are associated with Rab7, Rab9, mannose 6-phosphate receptor, syntaxin7, LAMP-1 and LAMP-2 (Vieira et al., [@B151]). The final product, phagolysosomes, express LAMPs but have lost most of the earlier endosomal markers. In addition, the phagolysosomes possess a number of complementary degradative properties, including a very low pH, hydrolytic enzymes for particle digestion, defensins and other bactericidal peptides, and the ability to generate toxic oxidative compounds (Amigorena and Savina, [@B6]; Rock et al., [@B117]).

Cellular material taken up by CD11b DCs rapidly ends up in fully matured phagolysosomes (Figures [3](#F3){ref-type="fig"}A--C; Savina et al., [@B127], [@B128]; Reboulet et al., [@B112]; Peng and Elkon, [@B105]). Colocalization studies show an association of phagocytosed materials with LAMP-1+ organelles and pulse-chase experiments show the degradation of \>80% of the material in less than 20 h (Figures [3](#F3){ref-type="fig"}A,B). As a result, Ag are quickly processed and either shuttled into MHC class II restricted pathways or simply degraded and disposed of. In contrast, cross-presenting DC subsets take up material from dying cells and hold these particles in immature endosomes for an extended period of time (Figures [3](#F3){ref-type="fig"}A--C). While CD8α DCs have degraded most of the material after 20 h, digestion is much slower than in CD11b DCs. Phagocytosed cellular particles in mcDCs are more colocalized with EEA-1 and less with LAMP-1 after 4 h of co-incubation with irradiated cells, indicating slower endosomal maturation (Figure [3](#F3){ref-type="fig"}A). Moreover, pulse-chase studies showed the persistence of materials over a 20-h time span (Figure [3](#F3){ref-type="fig"}B; Reboulet et al., [@B112]). This persistence of Ag in the mcDCs has been shown to prolong the cross-presentation of specific cell-associated Ag and thereby increase T cell priming (Savina et al., [@B127]; Reboulet et al., [@B112]; Peng and Elkon, [@B105]).

![**Unique trafficking of phagocytosed material in cross-presenting DCs**. **(A)** ImageStream analysis of the colocalization between internalized Violet labeled-irradiated cells and PE-labeled EEA-1 or LAMP-1 at 4 h (*n* \> 950 events/group). Colocalization was based upon Bright Detail Similarity score between the two markers. Scores of 0--1 represent minimal colocalization. As the markers of interest become more colocalized the score increases to reflect this similarity. **(B)** ImageStream analysis of the frequency of CFSE-containing DCs and the number of CFSE+ particles per DC 2 h and 20 h after the removal of irradiated CFSE-labeled cells. Decreases in particle frequency and number/cell were attributed to acidification of the endosome and the subsequent CFSE-quenching. **(C)** Differences in lysosomal acidification rate between DC populations as determined by flow cytometric analysis of dual-labeled pH-indicating beads.](fimmu-03-00041-g003){#F3}

As endosomal acidification causes the robust activation of lysosomal proteases and the subsequent destruction of Ag, acidification is considered to be poorly compatible with cross-presentation. Forced lysosomal acidification dramatically reduces cross-presentation while prevention of acidification has been shown to enhance cross-presentation (Savina et al., [@B127]; Amigorena and Savina, [@B6]; Reboulet et al., [@B112]). Though it was previously described that DCs have relative ineffective acidification of their lysosomes, the mechanism under pinning the sustained phagosome alkalinization was only recently unraveled. Studies by laboratory of Mellman and Amigorena indicate that this results from an incomplete assembly of V-ATPase in DC lysosomes and the Rab27-mediated recruitment of the NADPH NOX2. The NOX2-mediated generation of reactive oxygen species (ROS) in endocytic compartments causes the consumption of protons, followed by the active alkalinization of these compartments (Trombetta et al., [@B150]; Savina and Amigorena, [@B126]; Savina et al., [@B128]; Rock et al., [@B117]).

Acidification studies indicate that endosomes with cell-associated material in both CD8α DCs and mcDCs maintain a similar high/neutral pH for several hours post uptake of cell-associated antigens, which correlates with Ag persistence. Compared to CD8α DCs, mcDCs show decreased lysosomal acidification over a prolonged period of time, resulting in a less acidic endosomal compartment after 20 h (Figures [3](#F3){ref-type="fig"}B,C; Reboulet et al., [@B112]).

In both populations the treatment with diphenylene iodonium (DPI) -- an inhibitor of flavin-containing enzymes such as NOX2 -- accelerates lysosomal acidification, prevents Ag persistence, and rapidly decreases the cross-presenting capacity of both CD8α DCs and mcDCs, emphasizing the importance of endosomal acidification in their cross-presentation (Reboulet et al., [@B112]).

The mechanisms that govern the prolonged Ag persistence in mcDC remain unclear as the biogenesis of phagolysosomes still involves many poorly understood processes. Transcriptome analysis of CD8α DCs and mcDCs showed ≈20-fold higher expression of Cybb (NOX2) in mcDCs. In addition, differential expression of various R- and Q-SNAREs (soluble *N*-ethyl maleimide sensitive-factor attachment protein receptors), sorting nexins, and V-ATPases that have been suggested to play a role in vesicle transport and fusion are seen (Vieira et al., [@B151]; Cebrian et al., [@B22]). However, as most of these processes depend on active recruitment of these proteins to endosomal/lysosomal membranes, differences in expression levels might not be indicative of their degree of involvement. It is more likely that the nature of the phagocytosed particle -- including size -- and the receptors involved in their uptake dictate phagosome maturation (Peng and Elkon, [@B105]).

Processing and MHC I loading
----------------------------

As intact internalized Ag fill the cell, there are two proposed pathways by which they are cross-presented: the vacuolar and cytosolic pathways. The vacuolar pathway hypothesizes that cross-presented Ag are fully processed within the endosomes. The aminopeptidase IRAP facilitates the production of MHC class I-specific peptides that bind to the MHC molecule within the endosome. This pathway appears to be cathepsin S dependent and TAP independent (Shen et al., [@B137]; Chen and Jondal, [@B24]; Rock et al., [@B117]). In contrast, the cytosolic pathway requires minimally processed antigen to escape into the cytosol. Once in the cytosol, the Ag is processed by the proteasome, and generated peptides are shuttled into the lumen of the ER via sec61 or into phagosomes that have recruited ER components. The ER associated aminopeptidase ERAP actively clips the peptides to the proper length and TAP facilitates the loading into MHC class I (Rock et al., [@B117]).

Multiple studies indicate a dominant role for the cytosolic pathway in the processing of cell-associated Ag by cross-presenting DC subsets (Figure [4](#F4){ref-type="fig"}; Shen et al., [@B137]; Rock et al., [@B117]). Smaller particles, like those taken up by mcDCs and CD8α DCs (Figure [2](#F2){ref-type="fig"}C), are more rapidly and efficiently exported to the cytosol, a process that would drive the cytosolic pathway of cross-presentation (Rodriguez et al., [@B118]). Also, lactacystin and brefeldin A, inhibitors of the proteasome and Golgi transport, respectively, completely inhibit the ability of both CD8α DCs and mcDCs to activate Ag-specific CD8^+^ T cells against cell-associated Ag (Figure [4](#F4){ref-type="fig"}). A recent report by Cebrian et al. ([@B22]) implicates the SNARE protein Sec22b as an essential element of the cytosolic pathway. Depletion of Sec22b inhibits the recruitment of ER-resident proteins to the phagosome and phagolysosomal fusion was enhanced. As a result, antigens are rapidly degraded instead of being transported to the cytosol. These combined effects of Sec22b loss drastically reduce the cross-presentation of soluble and surface bound OVA as well as parasite and bacterial associated antigens. Interestingly, the presentation of both MHC class II and endogenous MHC class I restricted peptides is unaffected demonstrating significant separation between these processing pathways (Cebrian et al., [@B22]). Taken together, these data support the hypothesis that Ag must reach the cytosol, and eventually become associated with ER-derived proteins, to be cross-presented.

![**Proteasomal inhibitors effectively block cross-presentation in both CD8α DC and mcDC**. Splenic DC were incubated with irradiated actmOVA cells in the presence of indicated inhibitors. After 20 h, samples were fixed, sorted, and cultured with OVA-specific B3Z T cells to assess the cross-presentation of cell-associated antigens. Cells pulsed with OVA~257--264~ prior to fixation were used to demonstrate priming capacity. Responses are normalized to control treatment.](fimmu-03-00041-g004){#F4}

The maintenance of a more neutral pH correlates with delayed or reduced lysosomal protease activation. Cross-presenting DCs characteristically express lower levels of proteases and higher levels of protease inhibitors as compared to other APCs (Lennon-Dumenil et al., [@B93]; Trombetta et al., [@B150]). Pepstatin A, an inhibitor of acid proteases involved in lysosomal maturation and acidification, has no effect on the DCs capacity to cross-present. This demonstrates that protease mediated peptide production plays a minimal role in cross-presentation (Figure [4](#F4){ref-type="fig"}; Rock et al., [@B117]). Interestingly, leupeptin, an inhibitor of cysteine proteases essential for the vacuolar pathway, partially inhibits cross-presentation, but affected the mcDCs more than the CD8α DC subset. This suggests that mcDCs may utilize the vacuolar pathway for the processing of cell-associated Ag more than other subsets. In support of this, removal of either ERAP or IRAP results in only a 50% reduction in cross-presentation, suggesting the utilization of both pathways by cross-presenting DCs (Firat et al., [@B49]; Blanchard et al., [@B14]; Saveanu et al., [@B125]; Rock et al., [@B117]).

Effect of Autocrine Cytokine Production
=======================================

The cytokines produced by DCs in the context of cellular death and clearance drastically influence Ag processing, presentation and, subsequently, the capacity of the DC to prime T cells against cell-associated Ag (Voll et al., [@B152]; Fadok et al., [@B45]; Janssen et al., [@B74]; Chung et al., [@B26]; Green et al., [@B54]). While the induction of anti-inflammatory cytokines -- including IL-10 and TGF-β-upon uptake of apoptotic cells is relatively poor, various studies indicate that DC concurrently reduce their capacity to produce pro inflammatory cytokines (IL-1α/β, IL-6, IL-12, TNFα; Stuart et al., [@B143]; Morelli et al., [@B100]). This altered cytokine production profile has been suggested to become entrenched in the APC and to affect subsequent spontaneous and induced cytokine production (Stuart et al., [@B143]; Morelli et al., [@B100]; Kim et al., [@B81]).

Upon exposure to apoptotic cells, CD11b DCs induce the anti-inflammatory cytokines IL-10 and TGF-β (Hennies et al., [@B64]). CD8α DCs readily express the pro-inflammatory cytokines IL-12 and Type I IFN under inflammatory conditions (Hochrein et al., [@B68]; Heath et al., [@B62]; Naik et al., [@B101]), but demonstrate minimal induction of these and other cytokines, including IL-10 and TGF-β, in response to apoptotic cells (Morelli et al., [@B100]; Hennies et al., [@B64]; Janssen, unpublished). This is particularly interesting as CD8α DCs produce TGF-βduring steady state (Yamazaki et al., [@B161]), a cytokine heavily implicated in the induction and maintenance of peripheral tolerance (Erwig and Henson, [@B43]; Green et al., [@B54]). In contrast, mcDCs express the pro-inflammatory cytokines IL-1β and type I IFN upon exposure to dying cells (Table [1](#T1){ref-type="table"}; Hennies et al., [@B64]).

IL-10 and TGF-β have potent immunosuppressive properties and promote the induction of tolerance. Both have been shown to reduce Ag presentation by regulating the transcription of the class I heavy chain, β~2~M, tapasin, TAP, and components of the proteasome (Geiser et al., [@B53]; Ma and Niederkorn, [@B97]; Koppelman et al., [@B83]; Nandan and Reiner, [@B103]; Salazar-Onfray et al., [@B120]; Zeidler et al., [@B162]; Strobl and Knapp, [@B142]; Francois et al., [@B51]). The pro-inflammatory cytokine IL-12 is a critical mediator of CD8^+^ T cell activation as it drives the necessary help of CD4^+^ T cells toward a Th1 phenotype (Trinchieri, [@B148]; Trinchieri et al., [@B149]; Chang et al., [@B23]; Del Vecchio et al., [@B32]; Lee et al., [@B92]). In spite of this, IL-12 seems to have little autocrine effect on Ag processing by CD8α DCs (Grohmann et al., [@B56]; Janssen, unpublished) and its induction has been suggested to require additional signals, including TLR engagement, CD40L, IL-4 or IFN-γ (Hochrein et al., [@B67]; Hochrein et al., [@B68]; Reis e Sousa et al., [@B114]; Schulz et al., [@B133]). These additional stimuli -- or their sequelae -- positively affect the expression of the proteasomal subunits, TAP1 and TAP2, calnexin, calreticulin, tapasin, NOX2, and MHC class I.

Merocytic DCs produce pro-inflammatory cytokines in response to apoptotic cells without the apparent need for additional signals. While IL-1β is traditionally incorporated in maturation cocktails in the generation of human DCs, its does not significantly affect cross-presentation or cross-priming by mcDCs. mcDCs lacking IL-1RI or MyD88 display CD8^+^ T cell priming capacity similar to WT mcDCs (Janssen, unpublished). In contrast, type I IFN production by the mcDCs, and resulting autocrine signaling, is critical for this subset's enhanced cross-presentation and activation of CD8^+^ T cells against cell-associated Ag (Reboulet et al., [@B112]). Type I IFNs have been shown to affect the expression of various components of the Ag processing and loading machinery, including proteasome subunits, TAP, tapasin, calreticulin, NOX2, MHC, and various SNAREs (Cho et al., [@B25]; Tosello et al., [@B146]; Lattanzi et al., [@B91]). The importance of autocrine type I IFN production was illustrated in experiments where transfer of apoptotic cell-exposed mcDCs that lacked the type I IFN receptor (*ifnar*) showed significantly reduced priming of endogenous CD8^+^ T cells to cell-associated Ag compared to WT mcDCs. As CD8α DCs do not produce type I IFN upon apoptotic cell uptake (Hennies et al., [@B64]), the presence or absence of the type I IFNα/βR on CD8α DCs did not affect their priming capacity (Figure [5](#F5){ref-type="fig"}A). Further *in vitro* experiments showed that the reduction in priming correlated with reduced expression of the specific MHC-peptide complexes on the *ifnar*-mcDCs. No significant differences were observed in total MHC class I levels, suggesting that type I IFNs interfered relatively early in the process of Ag presentation.

![**Autocrine type I IFN signaling by mcDC affects CFSE loss on phagocytosed cellular particles suggesting changes in the lysosomal acidification rate**. **(A)** CD8α DCs and mcDCs from indicated strains were exposed to irradiated actmOVA cells *in vitro*, purified and transferred into WT recipients. Seven days later the endogenous CD8^+^ T cell response was analyzed. **(B,C)** ImageStream analysis comparing the frequency and size of internalized CFSE-labeled particles in CD8α DCs and mcDCs from WT and *ifnar−/−* mice. **(D)** Loss of delayed acidification in *ifnar−/−* mcDC as determined by ImageStream analysis using CFSE-labeled irradiated cells and a pulse-chase approach.](fimmu-03-00041-g005){#F5}

Image stream analysis of WT and *ifnar−/−* CD8α DCs and mcDCs exposed to dying cells *in vitro* indicated that type I IFN sensing did not affect the capacity for phagocytosis by either subset with regard to the frequency of phagocytosing cells, the number of particles per cell, or particle size (Figures [5](#F5){ref-type="fig"}B,C). However, pulse-chase studies indicated the absence of type I IFN sensing accelerated CFSE loss, suggesting increased endosomal acidification, and significantly increased degradation of endosomal materials in mcDCs (Figure [5](#F5){ref-type="fig"}D). This is in line with recent findings of Lorenzi et al. ([@B96]), who showed that pre-treatment of CD8α DCs with recombinant type I IFN, which is otherwise absent in these cultures, significantly increased Ag retention after engulfment of apoptotic cells. Increased retention correlated with decreased endosomal acidification and resulted in enhanced cross-presentation of cell-associated Ag (Lorenzi et al., [@B96]). Interestingly, two recent *in vivo* studies demonstrated a critical role for type I IFN sensing in DC in tumor rejection models. The authors showed that mice lacking *ifnar* in DC failed to reject highly immunogenic tumor cells and that CD8α DCs from these mice displayed defects in antigen cross-presentation to CD8^+^ T cells (Diamond et al., [@B37]; Fuertes et al., [@B52]).

The concept of type I IFNs affecting endosomal pH and regulating Ag retention provides an intriguing concept that could explain why so many DC populations that fail to cross-present under steady state conditions are capable of doing so under inflammatory conditions associated with type I IFNs (Di Pucchio et al., [@B36]; Segura et al., [@B136]; Kamphorst et al., [@B78]; de Brito et al., [@B30]).

Of Mice and Men
===============

While it is possible to perform extensive analysis on mouse DCs through the use of transgenic mice and the ability to remove specific organs, human DC studies are hampered by the limited availability of human lymphoid tissue and differences in DC surface markers. However, recent research indicates the existence of various human counterparts that -- albeit phenotypically different -- have functional similarities to mouse DCs. While the details on cross-presentation by human DCs are addressed elsewhere in this issue, it is noteworthy that cross-priming has been observed by human pDCs and the "CD8α DC"-like DCs that expresses BDCA3, XCR1, DNGR1/Clec9A (Hoeffel et al., [@B69]; Dorner et al., [@B38]; Bachem et al., [@B8]; Henri et al., [@B65]; Crozat et al., [@B29]). Both cell types seem to have the capacity to actively internalize small particles of dead cell material. In addition, human DCs -- like mouse DCs -- require the regulation of phagosomal and endosomal pH for efficient cross-priming (Hoeffel et al., [@B69]; Amigorena and Savina, [@B6]). Whether these human DCs also encompass the counterpart of the human mcDCs is unclear. If human mcDCs would behave like mouse mcDCs, they would be associated with lymphoid tissue and very rare in blood. In this case it is interesting to note that most experiments using blood-derived or *in vitro* generated pDCs/BDCA3-DCs required inclusion of type I IFN inducing ligands to reveal their cross-priming ability.

Concluding Remarks
==================

Under steady state conditions, cross-presentation of cell-associated Ag is a continuous process that is imperative for the maintenance of peripheral tolerance. While great strides have been made in the elucidation of the mechanisms that govern cross-presentation and subsequent cross-priming, there are still many questions to be answered. Little is known about the proteins that orchestrate vesicle composition and trafficking or the signals involved in the recruitment of these proteins. It is likely that these processes are influenced by the composition and "state of decay" of the dying cells, the receptors involved in uptake, and the nature and maturation state of the DC. Moreover, *in vivo*, signals in trans provided by bystander cells can significantly affect intrinsic mechanisms of cross-presentation by DCs. Although elucidation of these processes may be a daunting task, increased mechanistic insight into these pathways will have tremendous therapeutic potential in the fields of autoimmune disease, transplantation, and cancer.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors would like to thank Dr. C. Karp for critically reading the manuscript. This work is supported by NIH grant CA138617 (NCI) and AI079545 (NIAID) to Edith M. Janssen.

[^1]: Edited by: Christian Kurts, Friedrich-Wilhelms-Universität Bonn, Germany

[^2]: Reviewed by: Daniel Robert Engel, University Clinic of Bonn, Germany; Carlos Ardavin, Centro Nacional de Biotecnologia/Consejo Superior de Investigaciones Científicas, Spain

[^3]: This article was submitted to Frontiers in Antigen Presenting Cell Biology, a specialty of Frontiers in Immunology.
